Ohio Woman Exposed as Cancer Phony
Another cancer phony has been exposed. As is often the case, this one chose a blood cancer.
38 year-old Kimberlie Gustwiller of McComb, Ohio, is alleged to have swindled several thousand dollars from donors in order to "gain financial support." The donors were under the impression that McComb was suffering from "Stage IV non-Hodgkin’s lymphoma."
She has been charged with theft and was arraigned in Bowling Green Municipal Court by video from the Wood County jail.
Investigators got a subpoena for the woman's medical records and found no evidence that she had been diagnosed with non-Hodgkin's lymphoma or any cancer.
An organization called the North Baltimore Eagles had planned an October 20 benefit to raise money for Gustwiller. According to the Toledo Blade, they intend to go on with the event but will donate the money to a "truly deserving" cause.
Source: Toledoblade
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
